

Curtis R Pickering

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6196393/publications.pdf>

Version: 2024-02-01

69
papers

6,034
citations

147801
31
h-index

114465
63
g-index

72
all docs

72
docs citations

72
times ranked

10315
citing authors

#	ARTICLE	IF	CITATIONS
1	Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in <i>NOTCH1</i> . <i>Science</i> , 2011, 333, 1154-1157.	12.6	1,568
2	Mutational Landscape of Aggressive Cutaneous Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2014, 20, 6582-6592.	7.0	493
3	Integrative Genomic Characterization of Oral Squamous Cell Carcinoma Identifies Frequent Somatic Drivers. <i>Cancer Discovery</i> , 2013, 3, 770-781.	9.4	484
4	Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas. <i>Science Translational Medicine</i> , 2015, 7, 293ra104.	12.4	372
5	Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. <i>Cell Reports</i> , 2018, 23, 194-212.e6.	6.4	245
6	Loss of p53 drives neuron reprogramming in head and neck cancer. <i>Nature</i> , 2020, 578, 449-454.	27.8	241
7	Assembly and Initial Characterization of a Panel of 85 Genomically Validated Cell Lines from Diverse Head and Neck Tumor Sites. <i>Clinical Cancer Research</i> , 2011, 17, 7248-7264.	7.0	230
8	High intratumor genetic heterogeneity is related to worse outcome in patients with head and neck squamous cell carcinoma. <i>Cancer</i> , 2013, 119, 3034-3042.	4.1	180
9	Evolutionary Action Score of <i>TP53</i> Identifies High-Risk Mutations Associated with Decreased Survival and Increased Distant Metastases in Head and Neck Cancer. <i>Cancer Research</i> , 2015, 75, 1527-1536.	0.9	139
10	Squamous Cell Carcinoma of the Oral Tongue in Young Non-Smokers Is Genomically Similar to Tumors in Older Smokers. <i>Clinical Cancer Research</i> , 2014, 20, 3842-3848.	7.0	124
11	Key tumor suppressor genes inactivated by <i>enhancer</i> promoter methylation and somatic mutations in head and neck cancer. <i>Epigenetics</i> , 2014, 9, 1031-1046.	2.7	122
12	Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells. <i>Cancer</i> , 2011, 117, 2926-2938.	4.1	112
13	Chk1/2 Inhibition Overcomes the Cisplatin Resistance of Head and Neck Cancer Cells Secondary to the Loss of Functional p53. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 1860-1873.	4.1	108
14	Disruptive <i>TP53</i> Mutation Is Associated with Aggressive Disease Characteristics in an Orthotopic Murine Model of Oral Tongue Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 6658-6670.	7.0	94
15	Integrative Analysis Identifies a Novel <i>AXL</i> - <i>PI3 Kinase</i> - <i>PD-L1</i> Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 2713-2722.	7.0	91
16	APOBEC3A is an oral cancer prognostic biomarker in Taiwanese carriers of an APOBEC deletion polymorphism. <i>Nature Communications</i> , 2017, 8, 465.	12.8	89
17	Evolutionary Action Score of <i>TP53</i> Coding Variants Is Predictive of Platinum Response in Head and Neck Cancer Patients. <i>Cancer Research</i> , 2015, 75, 1205-1215.	0.9	78
18	Variations in HPV function are associated with survival in squamous cell carcinoma. <i>JCI Insight</i> , 2019, 4, .	5.0	67

#	ARTICLE	IF	CITATIONS
19	Proteomic Profiling Identifies PTK2/FAK as a Driver of Radioresistance in HPV-negative Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 4643-4650.	7.0	64
20	New DNA Methylation Markers and Global DNA Hypomethylation Are Associated with Oral Cancer Development. <i>Cancer Prevention Research</i> , 2015, 8, 1027-1035.	1.5	60
21	Lessons learned from next-generation sequencing in head and neck cancer. <i>Head and Neck</i> , 2013, 35, 454-463.	2.0	58
22	p38 Regulates Cyclooxygenase-2 in Human Mammary Epithelial Cells and Is Activated in Premalignant Tissue. <i>Cancer Research</i> , 2005, 65, 1792-1799.	0.9	53
23	p16INK4a Modulates p53 in Primary Human Mammary Epithelial Cells. <i>Cancer Research</i> , 2006, 66, 10325-10331.	0.9	53
24	Individualizing antimetabolic treatment strategies for head and neck squamous cell carcinoma based on TP53 mutational status. <i>Cancer</i> , 2012, 118, 711-721.	4.1	50
25	Genomic characterization of human papillomavirus-positive and -negative human squamous cell cancer cell lines. <i>Oncotarget</i> , 2017, 8, 86369-86383.	1.8	50
26	Coordinated Targeting of the EGFR Signaling Axis by MicroRNA-27a*. <i>Oncotarget</i> , 2013, 4, 1388-1398.	1.8	44
27	Prevalence of promoter mutations in the TERT gene in oral cavity squamous cell carcinoma. <i>Head and Neck</i> , 2017, 39, 1131-1137.	2.0	40
28	Identifying predictors of HPV-related head and neck squamous cell carcinoma progression and survival through patient-derived models. <i>International Journal of Cancer</i> , 2020, 147, 3236-3249.	5.1	40
29	CDKN2A/p16 Deletion in Head and Neck Cancer Cells Is Associated with CDK2 Activation, Replication Stress, and Vulnerability to CHK1 Inhibition. <i>Cancer Research</i> , 2018, 78, 781-797.	0.9	37
30	Whole-exome Sequencing in Penile Squamous Cell Carcinoma Uncovers Novel Prognostic Categorization and Drug Targets Similar to Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 2560-2570.	7.0	37
31	High-Risk TP53 Mutations Are Associated with Extranodal Extension in Oral Cavity Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 1727-1733.	7.0	36
32	PK1 Mediates NOTCH1-Mutated Head and Neck Squamous Carcinoma Vulnerability to Therapeutic PI3K/mTOR Inhibition. <i>Clinical Cancer Research</i> , 2019, 25, 3329-3340.	7.0	36
33	Lung Cancer Models Reveal Severe Acute Respiratory Syndrome Coronavirus 2-Induced Epithelial-to-Mesenchymal Transition Contributes to Coronavirus Disease 2019 Pathophysiology. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1821-1839.	1.1	34
34	Literature-based automated discovery of tumor suppressor p53 phosphorylation and inhibition by NEK2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 10666-10671.	7.1	33
35	HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells. <i>Head and Neck</i> , 2014, 36, 1547-1554.	2.0	31
36	Targeting DNA damage response in head and neck cancers through abrogation of cell cycle checkpoints. <i>International Journal of Radiation Biology</i> , 2021, 97, 1121-1128.	1.8	30

#	ARTICLE	IF	CITATIONS
37	Targeting resistance to radiation-immunotherapy in cold HNSCCs by modulating the Treg-dendritic cell axis. , 2021, 9, e001955.		28
38	Caspase-8 loss radiosensitizes head and neck squamous cell carcinoma to SMAC mimeticâ€“induced necroptosis. JCI Insight, 2020, 5, .	5.0	28
39	Replication Stress Leading to Apoptosis within the S-phase Contributes to Synergism between Vorinostat and AZD1775 in HNSCC Harboring High-Risk <i>TP53</i> Mutation. Clinical Cancer Research, 2017, 23, 6541-6554.	7.0	27
40	The mutational landscape of earlyâ€“and typicalâ€“onset oral tongue squamous cell carcinoma. Cancer, 2021, 127, 544-553.	4.1	27
41	Genetics and penile cancer. Current Opinion in Urology, 2019, 29, 364-370.	1.8	26
42	Comprehensive pharmacogenomic profiling of human papillomavirus-positive and -negative squamous cell carcinoma identifies sensitivity to aurora kinase inhibition in KMT2D mutants. Cancer Letters, 2018, 431, 64-72.	7.2	25
43	Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors. Cancer Letters, 2017, 392, 71-82.	7.2	22
44	Distinct pattern of <i>TP53</i> mutations in human immunodeficiency virusâ€“related head and neck squamous cell carcinoma. Cancer, 2018, 124, 84-94.	4.1	22
45	Inhibition of histone acetyltransferase function radiosensitizes CREBBP/EP300 mutants via repression of homologous recombination, potentially targeting a gain of function. Nature Communications, 2021, 12, 6340.	12.8	17
46	Mechanisms for the Generation of Two Quadruplications Associated with Split-Hand Malformation. Human Mutation, 2016, 37, 160-164.	2.5	16
47	Mutation allele frequency threshold does not affect prognostic analysis using next-generation sequencing in oral squamous cell carcinoma. BMC Cancer, 2018, 18, 758.	2.6	16
48	Fusobacterium is enriched in oral cancer and promotes induction of programmed death-ligand 1 (PD-L1). Neoplasia, 2022, 31, 100813.	5.3	14
49	How will we recruit, train, and retain physicians and scientists to conduct translational cancer research?. Cancer, 2015, 121, 806-816.	4.1	13
50	Biology of the Radio- and Chemo-Responsiveness in HPV Malignancies. Seminars in Radiation Oncology, 2021, 31, 274-285.	2.2	13
51	Genetic Changes Driving Immunosuppressive Microenvironments in Oral Premalignancy. Frontiers in Immunology, 2022, 13, 840923.	4.8	13
52	p16 Represses DNA Damage Repair via a Novel Ubiquitin-Dependent Signaling Cascade. Cancer Research, 2022, 82, 916-928.	0.9	13
53	Penile squamous cell carcinoma is genomically similar to other HPV-driven tumors.. Journal of Clinical Oncology, 2019, 37, 505-505.	1.6	12
54	Risk Stratification of Oral Potentially Malignant Disorders in Fanconi Anemia Patients Using Autofluorescence Imaging and Cytology-On-A Chip Assay. Translational Oncology, 2018, 11, 477-486.	3.7	11

#	ARTICLE	IF	CITATIONS
55	Mu-opioid receptor activation promotes in vitro and in vivo tumor growth in head and neck squamous cell carcinoma. Life Sciences, 2021, 278, 119541.	4.3	9
56	Predicting Outcome in Head and Neck Cancer: miRNAs with Potentially Big Effects. Clinical Cancer Research, 2019, 25, 1441-1442.	7.0	6
57	Functionally impactful TP53 mutations are associated with increased risk of extranodal extension in clinically advanced oral squamous cell carcinoma. Cancer, 2020, 126, 4498-4510.	4.1	6
58	Tumor immune microenvironment alterations in penile squamous cell carcinoma using multiplex immunofluorescence and image analysis approaches.. Journal of Clinical Oncology, 2020, 38, 4-4.	1.6	6
59	Disruption of TP63-miR-27a* Feedback Loop by Mutant TP53 in Head and Neck Cancer. Journal of the National Cancer Institute, 2020, 112, 266-277.	6.3	5
60	Induction chemotherapy with or without erlotinib in patients with head and neck squamous cell carcinoma amenable for surgical resection. Clinical Cancer Research, 2022, , .	7.0	3
61	Bcl-2 Inhibition or FBXW7 Mutation Sensitizes Solid Tumor Cells to HDAC Inhibition In Vitro but Could Prove Difficult to Validate in Patients. Cancer Discovery, 2013, 3, 258-259.	9.4	2
62	p16INK4a expression and survival outcomes in patients with penile squamous cell carcinoma: The M.D. Anderson Cancer Center Experience.. Journal of Clinical Oncology, 2020, 38, 5-5.	1.6	2
63	Evolutionary action score of TP53 analysis in pathologically high-risk HPV-negative head and neck cancer from a phase II clinical trial: NRG Oncology RTOG 0234.. Journal of Clinical Oncology, 2019, 37, 6010-6010.	1.6	2
64	Evolutionary Action Score of TP53 Analysis in Pathologically High-Risk Human Papillomavirus-Negative Head and Neck Cancer From a Phase 2 Clinical Trial: NRG Oncology Radiation Therapy Oncology Group 0234. Advances in Radiation Oncology, 2022, 7, 100989.	1.2	1
65	Unique training brings young scientists up to speed in translational research. DMM Disease Models and Mechanisms, 2009, 2, 211-211.	2.4	0
66	Sequencing HNC: Emergence of Notch Signaling. , 2014, , 303-323.		0
67	Induction chemotherapy with and without erlotinib in patients with oral cavity squamous cell carcinomas (OCSCCs) amenable for surgical resection.. Journal of Clinical Oncology, 2019, 37, 6067-6067.	1.6	0
68	Identifying adverse molecular features of HPV+ head and neck cancers using patient-derived models.. Journal of Clinical Oncology, 2019, 37, 6057-6057.	1.6	0
69	Association of radiation treatment failure in head and neck cancer with differential immune infiltrate.. Journal of Clinical Oncology, 2020, 38, 6558-6558.	1.6	0